Reviews Ambrisentan Tablets


No reviews yet.

Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009





Other reviews about Ambrisentan Tablets on wordpress

New Orphan Drug For Pulmonary Hypertension
  by heremias
On Friday June 15th 2007, the Food and Drug Administration (FDA) approved a new drug for the treatment of pulmonary arterial hypertension. Letairis (ambrisentan) is an endothelin receptor […]


GlaxoSmithKline - Products
  by El Horror
About - Every second: Distributes more than 35 doses of vaccine. - Every minute: More than 1,100 prescriptions are written for GSK products. - Every hour: Spends more than $562,000 to […]



Other reviews about Ambrisentan Tablets on web:

Learn about the prescription medication Letairis (Ambrisentan Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Letairis (Ambrisentan Tablets) Drug Information: Uses, Side ...


Ambrisentan tablets To return to the main entry click here . What are Ambrisentan tablets? AMBRISENTAN is used to treat a serious heart and lung Ambrisentan tablets: Information from Answers.com


Ambrisentan Brand names: LETAIRIS Drug Forms: Ambrisentan tablets (below) Ambrisentan Oral tablet Español: Ambrisentan, Tableta oral Ambrisentan Ambrisentan: Information from Answers.com


HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LETAIRIS ® tablets safely and effectively. LETAIRIS (ambrisentan) tablets for oral use


HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LETAIRIS® tablets safely and effectively. LETAIRIS (le-TAIR-is) Tablets (ambrisentan)


GILEAD SCIENCES, INC NDA 22-081 LETAIRIS (ambrisentan) Gilead Sciences, Inc. 3333 Walnut Street Boulder, CO 80301 RISK EVALUATION AND MITIGATION STRATEGY (REMS) I. GOAL(S): The risk ... LETAIRIS (le-TAIR-is) Tablets (ambrisentan)


Ambrisentan Oral tablet What is this medicine? AMBRISENTAN (am bri SEN tan) is used to treat pulmonary hypertension. This medicine may help make exercise and breathing easier. Ambrisentan


Ambrisentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural ... Buy Letairis (ambrisentan) 5mg Tablet Online


Letairis (ambrisentan) 5 and 10 mg tablets Drug Safety Labeling Changes July 2009 - MedWatch Letairis (ambrisentan) 5 and 10 mg tablet


Warnings: Oral route(Tablet) Elevations of liver aminotransferases (ALT, AST) have been reported with ambrisentan and serious liver injury has been reported with related drugs. Ambrisentan (Oral route)





Featured Reviews

Reviews Hyoscyamine

Levsin Drug Description Levsin® (hyoscyamine sulfate) Tablets USP DRUG DESCRIPTION What are the possible side effects of hyoscyamine? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Zyban

Zyban Drug Description ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets WARNING Serious neuropsychiatric events, including but not limited to depression, suicidal ideation, suicide attempt, and completed suicide have been...
Read More  |  Review This
Reviews Armodafinil

Nuvigil Drug Description NUVIGIL® (armodafinil) Tablets DRUG DESCRIPTION What are the possible side effects of armodafanil (Nuvigil)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Inapsine

Inapsine Drug Description INAPSINE® (droperidol) Injection For intravenous or intramuscular use only WARNING Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving Inapsine at doses at or...
Read More  |  Review This
Reviews Taxotere

Taxotere Drug Description TAXOTERE (docetaxel) Injection Concentrate, Intravenous Infusion WARNING The incidence of treatment-related mortality associated with TAXOTERE therapy is increased in patients with abnormal liver function,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....